Subcutaneous GM-CSF therapy (6 μg/kg per day) has been tried for treating PAP in another child with LPI, but was unsuccessful because the administration of GM-CSF had side effects and lead to excessive leukocytosis [34]. Here, CSF2 is linked to pulmonary alveolar proteinosis.